UBL4B Products

UBL4B Antibodies

Western Blot: UBL4B Antibody [NBP1-82054] - Lane 1: Marker [kDa] 250, 130, 95, 72, 55, 36, 28, 17, 10<br/>Lane 2: Negative control (vector only transfected HEK293T lysate)<br/>Lane 3: Over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (~3.1 kDa) in mammalian HEK293T cells, LY404349)Immunocytochemistry/Immunofluorescence: UBL4B Antibody [NBP1-82054] - Staining of human cell line U-2 OS shows positivity in cytoskeleton (intermediate filaments).
Species: Human
Applications: WB, ICC/IF, IHC, IHC-P, IF
Host: Rabbit Polyclonal
Western Blot: UBL4B Antibody (3B2) [H00164153-M04] - Analysis of UBL4B expression in transfected 293T cell line by UBL4B monoclonal antibody (M04), clone 3B2. Lane 1: UBL4B transfected lysatE (19.9 KDa). Lane 2: Non-transfected lysate.Sandwich ELISA: UBL4B Antibody (3B2) [H00164153-M04] - Detection limit for recombinant GST tagged UBL4B is 0.3 ng/ml as a capture antibody.
Species: Human
Applications: WB, ELISA, S-ELISA
Host: Mouse Monoclonal
Western Blot: UBL4B Antibody [H00164153-B01P] - Analysis of UBL4B expression in transfected 293T cell line by UBL4B polyclonal antibody.  Lane 1: UBL4B transfected lysate(19.14 KDa). Lane 2: Non-transfected lysate.
Species: Human
Applications: WB, ELISA
Host: Mouse Polyclonal

UBL4B Lysates

UBL4B Proteins

Species: Human
Applications: WB, ELISA, PA
Species: Human
Applications: B/N, Ctrl


Entrez Human
Uniprot Human
Product By Gene ID 164153
Alternate Names
  • ubiquitin-like protein 4B
  • FLJ25690
  • ubiquitin-like 4B

Diseases related to UBL4B

Discover more about diseases related to UBL4B.

Malignant Neoplasms
Malignant Female Reproductive System Neoplasm
Malignant Neoplasm Of Ovary
Ovarian Neoplasm

Pathways for UBL4B

View related products by pathway and learn more about each of the pathways below.


Bioinformatics Tool for UBL4B

Discover related pathways, diseases and genes to UBL4B. Need help? Read the Bioinformatics Tool Guide for instructions on using this tool.
Vizit™, under license from BioVista Inc.